Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orencia

- PMLiVE

Biogen scores mid-stage trial win for lupus drug BIIB059

Last approved treatment for Lupus was GSK's Benlysta in 2011

Bristol Myers Squibb logo

BMS, Acceleron Pharma’s Reblozyl to be reviewed by FDA expert panel

Could win approval in group of rare blood cancers

- PMLiVE

Amarin files fish oil-based heart drug Vascepa in Europe

FDA verdict is also due for expanded use of the drug

- PMLiVE

Y-mAbs files breakthrough neuroblastoma drug in US

Rare cancer type mostly affects babies and young children

- PMLiVE

Diurnal files adrenal insufficiency drug Alkindi in US

Could become only treatment for children with the condition

- PMLiVE

Incyte claims FDA priority review for bile duct cancer drug

Significant need for new therapies in hard-to-treat cancer type

- PMLiVE

FDA backs GBT’s sickle cell drug Oxbryta

Second new treatment for blood disorder to be approved this year

- PMLiVE

Roche scores FDA priority review for risdiplam in SMA

Potential rival to Novartis’ Zolgensma and Biogen’s Spinraza

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

- PMLiVE

FDA clears SK Life Science’s anti-epileptic drug Xcopri

Significantly reduced the frequency of seizures at all doses studied

Bristol Myers Squibb logo

BMS’ Opdivo/Yervoy combination fails to shine in melanoma

Combo therapy did not show significant benefit in key patient population

- PMLiVE

FDA clears Alnylam’s second RNAi drug for rare disease

Second drug in the class to be cleared by regulatory authority

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links